Singapore, 13 June 2014 -The Monetary Authority of Singapore (MAS) announced today that a facility for providing overnight Renminbi (RMB) liquidity to financial institutions in  Singapore will be launched on 1 July 2014.
MAS also welcomed the directive issued today by the People’s Bank of China (PBC) Nanjing branch that will allow eligible corporates and individuals in the Suzhou Industrial Park (SIP) to conduct cross-border RMB transactions with Singapore. These initiatives will further promote the international use of RMB and  facilitate the growth of the RMB offshore market in Singapore.
The overnight RMB liquidity facility will provide up to RMB 5 billion in overnight  funds on any given day. Singapore’s RMB market has grown rapidly, and the facility will  further bolster market confidence by giving financial institutions the assurance that their short-term RMB funding needs will be met. The facility complements the existing MAS RMB  facility that allows banks to borrow RMB funds on a term basis for trade, direct investment  and market stability purposes. Details of the overnight RMB liquidity facility will be made  available on MAS’ website on 1 July 2014.
MAS Deputy Managing Director, Ms Jacqueline Loh, said: “As the volume of RMB  activities grows in Singapore, the overnight RMB liquidity facility will help alleviate end-ofday funding strains of financial institutions. This will provide a conducive environment for the continued expansion of RMB activities in Singapore.” SIP Cross-border RMB Initiative
The SIP cross-border RMB initiative was part of the agreement reached at the 10th Joint Council for Bilateral Cooperation on 22 October 2013 to strengthen China-Singapore  financial cooperation. PBC’s directive will allow for a range of cross-border transactions:

  1. Banks in Singapore can conduct cross-border RMB lending to corporates in SIP;
  2. Corporates in SIP can issue RMB bonds in Singapore;
  3. Equity investment funds in SIP can conduct direct investment in corporates in Singapore; and
  4. Individuals in SIP can conduct RMB remittance between China and Singapore for the settlement of current account transactions and direct  investment in corporates in Singapore.

PBC Nanjing branch’s announcement can be accessed via this website: (see here) and the details of the rules can be accessed via this website: (see here)
Ms Loh added that: “The introduction of cross-border RMB channels between Singapore and SIP will facilitate greater financing for companies operating in the SIP,  encourage direct investment in corporates in Singapore and broaden the range of RMB  activities that can be conducted out of Singapore. We look forward to similar arrangements  being put in place in the near future to allow cross-border RMB transactions between Singapore and Tianjin Eco-City.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments
You May Also Like

NSP gets a boost to election campaign

by Andrew Loh The National Solidarity Party (NSP) has received a boost to…

Judge hands out deterrent sentence to Amos Yee’s assailant

Neo Gim Huah, the man who slapped teenage blogger Amos Yee outside…

Police warns of phone scams that claim to be from the Criminal Investigation Department

Members of the public should take caution if they receive any phone…

恐增强微生物抗药性 世卫吁多国停滥用抗生素

世界卫生组织(WHO)週一发表研究报告,指出部分国家滥用抗生素情况严重,世卫警告一旦人体习惯使用抗生素,会导致细菌对抗生素含抗药性,变为「超级细菌」,一旦强效抗生素失效,人类最终將失去治疗手段。 世卫必要药物部主任希尔呼吁各国尽快行动,如规定抗生素必须由医生处方使用,以杜绝病人不必要地滥用药物。 其中意大利、西班牙和日本更大量使用被列为「备用类」、即本应作为最后治疗手段的强效抗生素。 “抗生素”在药学上用于描述用于预防和治疗寄生虫、细菌、病毒和真菌感染的药物。抗生素耐药性是指细菌在经过抗生素治疗后存活的能力。因此,抗生素抗药性是微生物中抗药性的总称。它是自然发生的,但滥用抗菌药物,会加强微生物的抗药性。 世卫去年推出抗生素分级制,將抗生素分为「可用类」、「慎用类」、「备用类」三级,呼吁各国优先使用属於「可用类」的盘尼西林类抗生素,只在其余药物无效等情况下,才动用多黏菌素等「备用类」强效抗生素,以避免细菌一旦对强效药物呈抗药性,连带所有抗生素失效。 世卫的《抗生素消耗监测报告》,研究全球65个国家使用抗生素的情况。 报告显示,意大利、西班牙、日本等国家,经常使用「备用类」药物。意大利每日消耗的抗生素中,2%为「备用类」,较德国高3倍,更较英国高6倍。 日本平均每千名国民日均抗生素摄取量为14.19剂,数目仅为韩国的一半,但在使用「备用类」抗生素上,日本比例却高达1.1%,远高於韩国的0.2%。 蒙古消耗抗生素最严重 报告亦指出,在65个国家中,蒙古消耗抗生素情况最为严重,平均每千名国民日均抗生素摄取量达64.41剂。非洲国家布隆迪消耗量最低,日均摄取量为4.44剂。 在欧洲、中东国家中,荷兰日均抗生素摄取量达9.78剂,英国的用量较荷兰高一倍,土耳其则较英国再高1倍,日均摄取量达38.18剂。 报告不包括美国、中国、印度等国家。世卫在声明中强调,全国各国使用抗生素的差距悬殊,一方面反映部分国家滥用抗生素,另一方面亦反映部分国家缺乏渠道取得药物。…